Weightlifting Athlete Manuel Aguero Receives Sanction for Anti-Doping Rule Violation
Press Release
12th March 2020
USADA announced today that Manuel Aguero, of Miami, Fla., an athlete in the sport of weightlifting, has received a four-year suspension for an anti-doping rule violation after testing positive for multiple prohibited substances.
Aguero, 29, tested positive for amphetamine, modafinil and its metabolite modafinil acid, and the methylphenidate metabolite ritalinic acid as a result of an in-competition drug test conducted at the American Open Series on July 26, 2019. Amphetamine and modafinil are non-Specified Substances in the class of Stimulants, and methylphenidate is a Specified Substance in the class of Stimulants. Each substance is prohibited in-competition under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic and Paralympic Committee National Anti-Doping Policies, and the International Weightlifting Federation Anti-Doping Policy, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.
Augero’s four-year period of ineligibility began on November 13, 2019, the date his provisional suspension was imposed. In addition, Aguero
has been disqualified from competitive results obtained on and subsequent to July 26, 2019, the date his positive sample was collected, including forfeiture of any medals, points and prizes.
- Anti-Doping Anti-Doping Rule Violation in-competition drug test International Weightlifting Federation Anti-Doping Policy non-Specified Substances Stimulants United States Olympic and Paralympic Committee National Anti-Doping Policies USADA USADA Protocol for Olympic and Paralympic Movement Testing Weightlifting World Anti-Doping Agency (WADA) World Anti-Doping Agency Prohibited List World Anti-Doping Code
